Panelists discuss how the evaluation and treatment initiation processes for non-BCMA targeted bispecifics and BCMA-targeted bispecifics share core similarities in patient assessment and care coordination, but differ in specific premedication protocols, dosing strategies, and side effect management.
Panelists discuss the rationale behind combination strategies with bispecifics in relapsed/refractory multiple myeloma (R/R MM), highlighting key studies such as RedirecTT-1 for teclistamab and talquetamab, TRIMM-2 for talquetamab and daratumumab, and MagnetisMM-32 for elranatamab, along with considerations for step-up dosing and outpatient administration protocols.
Panelists discuss how data from the long-term update from CARTITUDE-4 reveal impressive overall response rates (ORRs) and duration of response (DOR) for ciltacabtagene autoleucel, reinforcing its effectiveness in treating lenalidomide-refractory multiple myeloma.
Panelists discuss how logistical barriers like drug access, insurance coverage, and managing infusion logistics have posed challenges in the implementation of GPRC5D-targeted therapies in community practice.
Experts on multiple myeloma outline current challenges in determining the optimal treatment strategy for patients with relapsed/refractory disease who are eligible for bispecifics and CAR T-cell therapy.
The panel concludes its discussion with key takeaways on unmet needs and evolving treatment paradigms in relapsed/refractory multiple myeloma.
BCMA testing tracks clinical changes faster without the need for marker expression vs monoclonal immunoglobulin, a conventional multiple myeloma marker.
Studies indicate that higher BCMA levels are associated with a greater need for therapy years following diagnosis for patients with smoldering myeloma.
With Martina Murphy, MD, collaborates with the Oncology Brothers to explore personalized treatment strategies for ovarian cancer, emphasizing dose reduction and the management of adverse effects to enhance patient care and outcomes.
With Martina Murphy, MD, the Oncology Brothers discuss maneuvering through different treatment options for ovarian cancer, emphasizing the need for personalized approaches to optimize patient care and outcomes.
With Martina Murphy, MD, the Oncology Brothers discuss maintenance therapies in ovarian cancer, focusing on their potential to prolong progression-free survival and improve quality of life for patients.
With Martina Murphy, MD, the Oncology Brothers discuss the role of adjuvant chemotherapy in early-stage endometrioid and clear cell ovarian cancer, highlighting its impact on improving patient outcomes and the importance of tailored treatment strategies.
With Martina Murphy, MD, the Oncology Brothers discuss the latest advancements in the diagnosis and treatment of epithelial ovarian, fallopian tube, and primary peritoneal cancers, emphasizing the importance of a multidisciplinary approach for optimal patient outcomes.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Panelists discuss how the TRIMM-2 study explores the potential of combining bispecific antibodies to enhance treatment efficacy in patients with relapsed/refractory multiple myeloma, potentially offering a novel therapeutic strategy for this difficult-to-treat condition.
Panelists discuss how Talquetamab, a novel GPRC5DxCD3 bispecific antibody, shows promising results in treating relapsed/refractory multiple myeloma based on the MonumenTAL-1 trial data, potentially offering a new therapeutic option for this challenging patient population.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
Panelists discuss how VRd (bortezomib, lenalidomide, dexamethasone) remains the standard frontline regimen for transplant-eligible newly diagnosed multiple myeloma (NDMM) patients, though some now consider adding daratumumab (dara-VRd) in high-risk cases.
Panelists discuss key takeaways from the analysis of long-term results, noting that these findings may influence their recommendations for first-line regimens in EGFR-mutant metastatic non–-small cell lung cancer. They highlight how they engage patients in discussions about treatment options, considering efficacy and safety, while addressing remaining unmet needs in this therapeutic area.
Panelists discuss how insights from the INTERCEPT, BESPOKE, COSMOS-CRC-01, and GALAXY studies are advancing our understanding of circulating tumor DNA’s (ctDNA) utility in colorectal cancer management, from early detection to treatment monitoring.
Panelists discuss how the DYNAMIC trial data demonstrate the potential of circulating tumor DNA (ctDNA)–guided therapy to inform and optimize adjuvant chemotherapy decisions in patients with stage II colon cancer.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
Panelists discuss key takeaways from the analysis and offer clinical pearls on incorporating prophylactic dexamethasone 8 mg into treatment with amivantamab and lazertinib for community colleagues.
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Panelists discuss how ide-cel, a CAR T-cell therapy, demonstrates promising real-world outcomes in patients with relapsed/refractory multiple myeloma, potentially offering a valuable treatment option for this challenging patient population.
Panelists discuss how novel therapeutic approaches and combination regimens are reshaping the landscape of treatment for patients with relapsed/refractory multiple myeloma, offering new hope for improved outcomes and quality of life.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
